Country: Unjoni Ewropea
Lingwa: Malti
Sors: EMA (European Medicines Agency)
tolcapone
Viatris Healthcare Limited
N04BX01
tolcapone
Kontra l-marda ta ' Parkinson id-drogi, aġenti dopaminerġiċi Oħra
Marda ta 'Parkinson
Tasmar hija indikata fil kombinazzjoni ma ' ticlopidine hydrochloride / benserazide jew ticlopidine hydrochloride / carbidopa għall-użu fil-pazjenti ma ticlopidine hydrochloride-responsivi idiopathic Parkinson's marda u oxxillazzjonijiet vetturi bil-mutur, li naqas milli jirrispondi għal jew huma intolerant ta ' xulxin inibituri ta ' catechol-O-methyltransferase (COMT). Minħabba r-riskju ta potenzjalment fatali, ħsara fil-fwied akut, Tasmar ma għandhomx jiġu kkunsidrati bħala l-ewwel linja ta 'trattament miżjud ma' levodopa / benserazide jew levodopa / carbidopa. Peress li Tasmar għandu jiġi użat biss flimkien ma 'levodopa / benserazide u b'levodopa / carbidopa, l-tagħrif preskritt individwalment għal dawn l-sustanzi ta' levodopa hija applikabbli għall-użu tagħhom flimkien ma ' Tasmar.
Revision: 24
Awtorizzat
1997-08-27
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Tasmar 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg tolcapone. Excipients with known effect Each film-coated tablet contains 7.5 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pale to light yellow, hexagonal, biconvex, film-coated tablet. “TASMAR” and “100” are engraved on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol- _O_ -methyltransferase (COMT) inhibitors (see section 5.1). Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first- line adjunct therapy to levodopa/benserazide or levodopa/carbidopa (see sections 4.4 and 4.8). Since Tasmar should be used only in combination with levodopa/benserazide and levodopa/carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Paediatric population _ Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy. There is no relevant indication for use in children and adolescents. _Elderly _ No dose adjustment of Tasmar is recommended for elderly patients. _Hepatic impairment (see section 4.3) _ Tasmar is contraindicated for patients with liver disease or increased liver enzymes. _ _ _Renal impairment (see section 5.2) _ No dose adjustment of Tasmar is recommended for patients with mild or moderate renal impairment (creatinine clearance of 30 ml/min or greater). Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution. No informatio Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Tasmar 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg tolcapone. Excipients with known effect Each film-coated tablet contains 7.5 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pale to light yellow, hexagonal, biconvex, film-coated tablet. “TASMAR” and “100” are engraved on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tasmar is indicated in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol- _O_ -methyltransferase (COMT) inhibitors (see section 5.1). Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first- line adjunct therapy to levodopa/benserazide or levodopa/carbidopa (see sections 4.4 and 4.8). Since Tasmar should be used only in combination with levodopa/benserazide and levodopa/carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Paediatric population _ Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy. There is no relevant indication for use in children and adolescents. _Elderly _ No dose adjustment of Tasmar is recommended for elderly patients. _Hepatic impairment (see section 4.3) _ Tasmar is contraindicated for patients with liver disease or increased liver enzymes. _ _ _Renal impairment (see section 5.2) _ No dose adjustment of Tasmar is recommended for patients with mild or moderate renal impairment (creatinine clearance of 30 ml/min or greater). Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution. No informatio Aqra d-dokument sħiħ